These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 18290849

  • 41. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
    Jung P, Beyerle A, Ziemann U.
    Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
    [Abstract] [Full Text] [Related]

  • 42. Comparison of the Kurtkze expanded disability status scale and the functional independence measure: measures of multiple sclerosis-related disability.
    Rabadi MH, Vincent AS.
    Disabil Rehabil; 2013 May; 35(22):1877-84. PubMed ID: 23600712
    [Abstract] [Full Text] [Related]

  • 43. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ.
    Neurology; 2005 Mar 22; 64(6):992-5. PubMed ID: 15781814
    [Abstract] [Full Text] [Related]

  • 44. How similar are commonly combined criteria for EDSS progression in multiple sclerosis?
    Kragt JJ, Nielsen IM, van der Linden FA, Uitdehaag BM, Polman CH.
    Mult Scler; 2006 Dec 22; 12(6):782-6. PubMed ID: 17263007
    [Abstract] [Full Text] [Related]

  • 45. Disease activity and disability evolution under glatiramer acetate: a clinical approach.
    Vacaras V, Major ZZ, Seewooram R, Major KA, Muresanu DF, Buzoianu AD.
    Neuropsychopharmacol Hung; 2014 Mar 22; 16(1):11-8. PubMed ID: 24687014
    [Abstract] [Full Text] [Related]

  • 46. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL, Devonshire V, Tremlett H.
    Neurology; 2007 Feb 13; 68(7):496-500. PubMed ID: 17296915
    [Abstract] [Full Text] [Related]

  • 47. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
    Miller A, Spada V, Beerkircher D, Kreitman RR.
    Mult Scler; 2008 May 13; 14(4):494-9. PubMed ID: 18208875
    [Abstract] [Full Text] [Related]

  • 48. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.
    J Neurol Sci; 2012 Dec 15; 323(1-2):104-12. PubMed ID: 23006974
    [Abstract] [Full Text] [Related]

  • 49. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.
    Rudick RA, Cutter G, Reingold S.
    Mult Scler; 2002 Oct 15; 8(5):359-65. PubMed ID: 12356200
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.
    Clin Ther; 2010 Jun 15; 32(6):1061-6. PubMed ID: 20637960
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J, Nos C, Tintoré M, Borrás C, Galán I, Comabella M, Montalban X.
    Ann Neurol; 2002 Oct 15; 52(4):400-6. PubMed ID: 12325067
    [Abstract] [Full Text] [Related]

  • 54. Evaluation of clinical parameters during and after treatment of attack in patients with clinically isolated syndrome: comparison of the results with that of multiple sclerosis patients.
    Piri Cinar B, Ozakbas S, Idiman E.
    Clin Neurol Neurosurg; 2013 Dec 15; 115(12):2432-7. PubMed ID: 24140010
    [Abstract] [Full Text] [Related]

  • 55. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
    Fox EJ, Sullivan HC, Gazda SK, Mayer L, O'Donnell L, Melia K, Lake SL.
    Eur J Neurol; 2012 Feb 15; 19(2):307-11. PubMed ID: 21899662
    [Abstract] [Full Text] [Related]

  • 56. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
    Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ.
    Neurology; 2011 Oct 25; 77(17):1611-8. PubMed ID: 22025459
    [Abstract] [Full Text] [Related]

  • 57. The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis.
    Balkuv E, Varoglu AO, Isik N, Isbilen B, Duruyen S, Basaran R, Kocer A.
    Mult Scler Relat Disord; 2016 Jul 25; 8():131-5. PubMed ID: 27456888
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Assessment of driving performance in patients with relapsing-remitting multiple sclerosis by a driving simulator.
    Kotterba S, Orth M, Eren E, Fangerau T, Sindern E.
    Eur Neurol; 2003 Jul 25; 50(3):160-4. PubMed ID: 14530622
    [Abstract] [Full Text] [Related]

  • 60. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V.
    Eur J Neurol; 2010 Jan 25; 17(1):31-7. PubMed ID: 19614963
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.